scholarly journals Analysis of Let-7 Family miRNA in Plasma as Potential Predictive Biomarkers of Diagnosis for Papillary Thyroid Cancer

Diagnostics ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. 130 ◽  
Author(s):  
Ewelina Perdas ◽  
Robert Stawski ◽  
Krzysztof Kaczka ◽  
Maria Zubrzycka
Keyword(s):  
Thyroid Cancer ◽  
Predictive Biomarkers ◽  
Radical Resection ◽  
Digital Pcr ◽  
Droplet Digital Pcr ◽  
Control Group ◽  
Papillary Thyroid ◽  
Healthy Control ◽  
Noninvasive Biomarkers ◽  
Common Histological Type

The most common histological type of thyroid cancer is papillary thyroid carcinoma (PTC). Radical resection of the thyroid gland is currently the recommended method of treatment. Almost 75% of thyroidectomies performed just for diagnostic purposes are benign. Thus, the confirmation of innovative and more precise noninvasive biomarkers holds promise for the detection of PTC, which may decrease the number of unnecessary thyroid lobectomies. In this work, using the droplet digital PCR (ddPCR) method, we have analyzed the level of five miRNAs (let-7a, let-7c, let-7d, let-7f, and let-7i) in the plasma of patients with PTC and compared them with those of a healthy control group to investigate whether miRNAs also have value in the management of PTC. Levels of four miRNAs, namely let-7a, let-7c, let-7d, and let-7f, were significantly higher in PTC patients than healthy controls. Thus, the analysis of circulating let-7 can be a useful tool and support the currently used methods for PTC diagnosis. However, our observation requires further research on a larger patient group.

scholarly journals ID: 1034 Potential cancer predictive biomarkers: a case of papillary thyroid cancer

2017 ◽  
Vol 4 (S) ◽  
pp. 109
Author(s):  
Marko Gerić ◽  
Renato Janušić ◽  
Božena Šarčević ◽  
Vera Garaj-Vrhovac
Keyword(s):  
Thyroid Cancer ◽  
Comet Assay ◽  
Papillary Thyroid Cancer ◽  
Micronucleus Test ◽  
Human Peripheral Blood ◽  
Predictive Biomarkers ◽  
Control Group ◽  
Papillary Thyroid ◽  
Female Population ◽  
Genome Damage

Thyroid cancer represents 2.1% of new cancer cases, yet it is the most common endocrine cancer and one of the fastest growing cancer types in the world. The incidence of thyroid cancer is the highest in elderly population (60-69 years), but novel data suggest decline in age when this cancer is frequently diagnosed to 50-59 years. Thyroid cancer is 2-4-fold more common in female population what is usually associated with female hormones and the differences in oxidative stress levels. Since the WHO suggest that roughly 30% of cancer can be prevented, the aim of this study was to evaluate the role of micronucleus test and comet assay as cancer predictive biomarkers.  In this study, 36 patients with papillary thyroid cancer (PTC) were recruited in accordance with all ethical standards. The average age of the group was 52±14 years, 28:8 female:male ratio, and 33% of active smokers. Control group was matched for age, gender, and smoking habits (52±14 years, 28:8 female:male ratio, and 33% of active smokers).  The number of micronucleated (MNed) cells in human peripheral blood lymphocytes was significantly higher (p<0.05) in PTC group (12.94±5.81) compared to control group (4.36±2.58). Additionally, the comet assay tail moment (TM) was also significantly (p<0.05) higher in the PTC group compared to control group (0.39±0.71 vs 0.14±0.05). These results indicate that people with PTC had more genome damage compared to healthy controls. The immunohistochemical analysis of thyroid revealed 97.2% BRAF positive and 20.6% RET/PTC positive samples.  Taken together, the PTC group had more DNA damage what is associated with high prevalence of BRAF mutations and RET/PTC translocations as a consequence of disrupted genome integrity. The results imply that cytogenetic tools might be used in human biomonitoring for identification of high-risk groups but further research is needed to assess normal and cut-off values.

scholarly journals Sepsis Diagnostics: Intensive Care Scoring Systems Superior to MicroRNA Biomarker Testing

Diagnostics ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 701
Author(s):  
Fabian Link ◽  
Knut Krohn ◽  
Anna-Maria Burgdorff ◽  
Annett Christel ◽  
Julia Schumann
Keyword(s):  
Intensive Care ◽  
Scoring Systems ◽  
Digital Pcr ◽  
Absolute Quantification ◽  
Medical Problem ◽  
Control Group ◽  
Multiple Parameters ◽  
Sepsis Diagnosis ◽  
Intensive Care Patients ◽  
Healthy Control

Sepsis represents a serious medical problem accounting for numerous deaths of critically ill patients in intensive care units (ICUs). An early, sensitive, and specific diagnosis is considered a key element for improving the outcome of sepsis patients. In addition to classical laboratory markers, ICU scoring systems and serum miRNAs are discussed as potential sepsis biomarkers. In the present prospective observational study, the suitability of miRNAs in sepsis diagnosis was tested based on proper validated and normalized data (i.e., absolute quantification by means of Droplet Digital PCR (ddPCR)) in direct comparison to classical sepsis markers and ICU scores within the same patient cohort. Therefore, blood samples of septic intensive care patients (n = 12) taken at day of admission at ICU were compared to non-septic intensive care patients (n = 12) and a healthy control group (n = 12). Our analysis indicates that all tested biomarkers have only a moderate informative power and do not allow an unequivocal differentiation between septic and non-septic ICU patients. In conclusion, there is no standalone laboratory parameter that enables a reliable diagnosis of sepsis. miRNAs are not superior to classical parameters in this respect. It seems recommendable to measure multiple parameters and scores and to interpret them with regard to the clinical presentation.

scholarly journals BAX gene (−248 G > A) polymorphism in a sample of patients diagnosed with thyroid cancer in the Federal District, Brazil

2021 ◽  
pp. 172460082110575
Author(s):  
Ligia C.A. Cardoso-Duarte ◽  
Caroline F. Fratelli ◽  
Alexandre S.R. Pereira ◽  
Jéssica Nayane Gomes de Souza ◽  
Renata de Souza Freitas ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Protective Factor ◽  
Federal District ◽  
Genotypic Difference ◽  
Control Group ◽  
Nucleotide Polymorphisms ◽  
Papillary Thyroid ◽  
Genotype Frequencies ◽  
Bax Gene

Introduction Papillary thyroid cancer corresponds to approximately 1% of all carcinomas; nevertheless, it is the most prevalent endocrine neoplasm in the world. Studies reveal that the BAX (−248 G > A) polymorphism may be associated with negative regulation of BAX gene transcription activity, causing a decrease in its protein expression. Objective The present study aimed to describe the genotype and allele frequencies of BAX single nucleotide polymorphisms (−248 G > A) (rs4645878) in the research patients, and to associate its presence with susceptibility to papillary thyroid cancer. Methods This case-control study was conducted with 30 patients with papillary thyroid cancer. For the evaluation of genetic polymorphisms, the polymerase chain reaction-restriction fragment length polymorphism technique was employed. Allele and genotype frequencies were estimated using the SPSS program, and significant associations were considered when p < 0.05. Results There was a significant genotypic difference between papillary thyroid cancer and the control group (p = 0.042). The GG genotype provided a protective factor for papillary thyroid cancer (p = 0.012, odds ratio (OR) = 0.313; confidence interval (CI) = 0.123–0.794). Likewise the G allele was a protective factor for papillary thyroid cancer (p = 0.009; OR = 0.360; CI = 0.163–0.793). The BAX gene polymorphism (−248 G > A) was associated with papillary thyroid cancer. Conclusion BAX (−248 G > A) GG genotype carriers, or at least one mutated allele, was associated with papillary thyroid cancer in the Brazilian population studied, and the G allele presence is considered a protective factor against papillary thyroid cancer occurrence.

scholarly journals Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy

2020 ◽  
Vol 9 (8) ◽  
pp. 2481
Author(s):  
Kirk Jensen ◽  
Shilpa Thakur ◽  
Aneeta Patel ◽  
Maria Cecilia Mendonca-Torres ◽  
John Costello ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Liquid Biopsy ◽  
Digital Pcr ◽  
Response To Therapy ◽  
Response To Treatment ◽  
Papillary Thyroid ◽  
Primary Tumors ◽  
Promising Tool ◽  
Increased Risk

The detection of rare mutational targets in plasma (liquid biopsy) has emerged as a promising tool for the assessment of patients with cancer. We determined the presence of cell-free DNA containing the BRAFV600E mutations (cfBRAFV600E) in plasma samples from 57 patients with papillary thyroid cancer (PTC) with somatic BRAFV600E mutation-positive primary tumors using microfluidic digital PCR, and co-amplification at lower denaturation temperature (COLD) PCR. Mutant cfBRAFV600E alleles were detected in 24/57 (42.1%) of the examined patients. The presence of cfBRAFV600E was significantly associated with tumor size (p = 0.03), multifocal patterns of growth (p = 0.03), the presence of extrathyroidal gross extension (p = 0.02) and the presence of pulmonary micrometastases (p = 0.04). In patients with low-, intermediate- and high-risk PTCs, cfBRAFV600E was detected in 4/19 (21.0%), 8/22 (36.3%) and 12/16 (75.0%) of cases, respectively. Patients with detectable cfBRAFV600E were characterized by a 4.68 times higher likelihood of non-excellent response to therapy, as compared to patients without detectable cfBRAFV600E (OR (odds ratios), 4.68; 95% CI (confidence intervals)) 1.26–17.32; p = 0.02). In summary, the combination of digital polymerase chain reaction (dPCR) with COLD-PCR enables the detection of BRAFV600E in the liquid biopsy from patients with PTCs and could prove useful for the identification of patients with PTC at an increased risk for a structurally or biochemically incomplete or indeterminate response to treatment.

scholarly journals Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Tomasz Stępień ◽  
Mateusz Brożyna ◽  
Krzysztof Kuzdak ◽  
Ewelina Motylewska ◽  
Jan Komorowski ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Protease Inhibitor ◽  
Papillary Thyroid Cancer ◽  
Preoperative Diagnosis ◽  
Secretory Leukocyte Protease Inhibitor ◽  
Control Group ◽  
Serum Concentrations ◽  
Papillary Thyroid ◽  
Blood Samples ◽  
Protease Nexin

Introduction. SERPINE2 and secretory leukocyte protease inhibitor (SLPI) are proteins with anticoagulant properties which could promote solid tumor growth. However, their role in the pathogenesis of thyroid cancer has not been determined. Materials and Methods. The aim of this study was to assess serum SERPINE2 and SLPI concentrations in a group of 36 patients with papillary thyroid cancer (PTC) and a group of 19 subjects with multinodular nontoxic goiter (MNG). The control group (CG) consisted of 20 healthy volunteers. Blood samples were collected one day before surgery. Serum SERPINE2 and SLPI concentrations were measured using specific ELISA methods. Results. Significantly higher concentrations of SERPINE2 and SLPI were found in patients with PTC as compared with MNG and controls. Positive correlation was found between SERPINE2 and SLPI concentrations in PTC patients. The levels of SERPINE2 and SLPI did not differ significantly between MNG and healthy controls. Conclusions. Our results indicate that SERPINE2 and SLPI play a significant role in the development of papillary thyroid cancer and imply that the evaluation of serum concentrations of both anticoagulant molecules may be considered as additional marker for the differentiation of malignancies during the preoperative diagnosis of patients with thyroid gland tumors.

Molecular genetic factors in the development of papillary thyroid cancer in the Kazakh population

2018 ◽  
Vol 64 (3) ◽  
Author(s):  
Mayra Zhaksimanovna Espenbetova ◽  
Natalya Egorovna Glushkova ◽  
Ainur Serikovna Krykpayeva
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Case Control Study ◽  
Effective Means ◽  
Molecular Genetic ◽  
Control Group ◽  
Papillary Thyroid ◽  
Similar Work ◽  
Kazakh Population ◽  
Control Study

Introduction. In the last decade several population studies on the association of the genes NKX2-1 and FOXE1 with sporadic papillary thyroid cancer were conducted. In the Kazakh population of similar work to date were not conducted. The aim of this study was to study the genetic association of the FOXE1 (rs9655313) and NKX2-1 (rs944289) oncomarkers with papillary thyroid cancer in the Kazakh population. Materials and methods. We conducted a case-control study that allows us to retrospectively evaluate the association of NKX2-1 and FOXE1 genes and papillary thyroid cancer. Results. The frequency distribution of FOXE1 rs965513 polymorphism in the group of papillary thyroid cancer and the control group detected by healthy individuals was significantly different (χ2 = 100.09, D.f. = 2, p = 0.000). In the group of cases, the AA genotype (17.5%) was in three times more often compared with the control group (5.1%). The GG variant had a lower frequency in the group of persons of papillary thyroid cancer (37.9%) against the control group (61.4%), the odds ratio (OR) in the FOXE1 rs965513 group was 2.367. The distribution of the NKX2-1 (rs944289) polymorphism frequencies in the compared groups of values were significantly different (χ2 = 100.09, D.f. = 2, p = 0.000). In the group of cases, the genotype of TT (30.5%) against the control group (20.7%) was 1.5 times more common. The SS variant had a lower frequency of occurrence in the group of persons of papillary thyroid cancer (19.8%) against the control group (28.9%), OR in NKX2-1 (rs944289) group was 1.46. Conclusion. Carrying out screening for carriers of FOXE1 rs965513 and NKX2-1 (rs944289) can become an effective means of early diagnosis with a high frequency of its spread and associations with cases of papillary thyroid cancer in the Kazakh population.

scholarly journals INSULIN-LIKE GROWTH FACTORS IN THE SERUM OF PATIENTS WITH PAPILLARY THYROID CANCER

2021 ◽  
Vol 74 (8) ◽  
pp. 1925-1930
Author(s):  
Nataliia S. Pidchenko ◽  
Mykola V. Krasnoselskyi ◽  
Nataliia A. Mitriaieva ◽  
Lidiya V. Grebenik ◽  
Olha M. Astapieva ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Growth Factors ◽  
Growth Factor ◽  
Blood Serum ◽  
Papillary Thyroid Cancer ◽  
The Body ◽  
Control Group ◽  
Insulin Like Growth Factor ◽  
Papillary Thyroid ◽  
Insulin Like Growth Factors

The aim is to study the level of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-2 (IGF-2) in the blood serum of patients with papillary thyroid cancer, depending on the main clinical and morphological features of the disease. Materials and methods: The material was the information about 60 patients with papillary thyroid cancer (group 1). In group 2 there were 10 patients without oncopathology. All patients underwent clinical examination after total thyroidectomy before special treatment (radioiodine therapy): ultrasound diagnosis of the neck, confirmed diagnosis of papillary thyroid cancer by morphological examination of operative material. All patients underwent anthropometric studies (height, weight), on the basis of which the body mass index (BMI) was calculated. The study program also included determination of the level of thyroid-stimulating hormone of the pituitary gland (TSH), thyroglobulin (TG), antibodies to thyroglobulin (AB-TG). It was also determined the serum glucose level. In order to assess insulin resistance, the HOMA-IR index was calculated. All patients were tested for serum IGF-1 and IGF-2. Results: In the blood serum of patients with papillary thyroid cancer in 63% of patients the level of IGF-1 and in 85% – IGF-2 was probably higher than in the control group. There is a relationship between the level of IGF-1, IGF-2 and elevated level of proliferating factor – insulin in the serum of patients with papillary thyroid cancer. This may indicate an aggressive potential of the disease (i.e. clinical data on the prevalence of papillary thyroid cancer coincide with laboratory data). There was found a relationship between the expression of IGF-1, IGF-2 and insulin: at elevated levels of insulin> 24.9 μIU/ml, IGF-1 increases 4.2 times, and IGF-2 – 2.5 times. Evaluation of the relationship between the level of IGF-1 and IGF-2 and cervical lymph node involvement shows that in the absence of lesion (N0) there is an increase in these indicators by 2.2 and 1.8 times, respectively. Conclusions: The signaling system of insulin-like growth factors (IGF-1 and IGF-2) plays an important role in the occurrence and progression of malignant tumors. It is especially true for papillary thyroid cancer, so its components can be considered as potential diagnostic and prognostic markers of the disease and targets for anticancer therapy.

scholarly journals Leptin: A Correlated Peptide to Papillary Thyroid Carcinoma?

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Mehdi Hedayati ◽  
Parichehr Yaghmaei ◽  
Zahra Pooyamanesh ◽  
Marjan Zarif Yeganeh ◽  
Laleh Hoghooghi Rad
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Peptide Hormone ◽  
Control Group ◽  
Papillary Thyroid ◽  
Fat Tissue ◽  
Serum Thyroxine ◽  
Cancer Group ◽  
Specific Tumor ◽  
Significant Difference

Introduction. Leptin as an adipose-tissue-related peptide hormone contributes to the control of food intake, energy expenditure, and other activities such as cell proliferation. Therefore, association of leptin level with thyroid cancer has been suggested recently. Considering that thyroid cancer is the most common endocrine cancer, the aim of this study was evaluation of leptin levels in thyroid cancer.Materials and Methods. 83 patients with papillary thyroid cancer (35 males and 48 females) with 90 healthy persons as control group (40 male and 50 females) were selected. serum thyroxine, thyrotropin, and leptin levels were determined in both groups. As a body fat tissue affects leptin level, so height and weight were measured and body mass index was calculated too.Results. There was no statistically significant difference in age, serum Thyroxine, and Thyrotropin levels. BMI in women was more than in men in both groups. Serum leptin levels in thyroid cancer group were significantly higher than control group (P<0.05).Conclusion. The results of this study showed an acceptable association between the hormone Leptin levels with papillary thyroid cancer, so it may be considerad as a correlated peptide which may help in the diagnosis or confirmation of thyroid cancer beside in other specific tumor markers.

scholarly journals Platelet Activation and Inflammation in Patients with Papillary Thyroid Cancer

Diagnostics ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. 1959
Author(s):  
Sorina Martin ◽  
Theodor Mustata ◽  
Oana Enache ◽  
Oana Ion ◽  
Andreea Chifulescu ◽  
...  
Keyword(s):  
Platelet Count ◽  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Inflammatory Markers ◽  
Control Group ◽  
Thyroid Disorders ◽  
Papillary Thyroid ◽  
Platelet Indices ◽  
Benign Thyroid Disorders ◽  
Benign Thyroid

Background: The primary endpoint was to analyze the preoperatory inflammatory markers and platelet indices in papillary thyroid cancer (PTC) patients compared with patients with benign thyroid pathology. The secondary endpoints were to analyze the relationship between these markers and the pathological features of PTC and to compare their pre- and postoperative levels in PTC patients. Methods: In this retrospective case-control study, we analyzed the files of 1183 patients submitted to thyroidectomy between January 2012 and December 2018. A total of 234 patients with PTC (mean age 51.54 ± 13.10 years, 84.6% females) were compared with an age-, gender- and BMI-matched control group of 108 patients with histologic benign thyroid disorders. Results: PTC patients had higher platelet count (PLT) (p = 0.011), plateletcrit (PCT) (p = 0.006), neutrophil (p = 0.022) and fibrinogen (p = 0.005) levels. Subgroup analysis showed that PTC females had higher PLT (p = 0.006), PCT (p < 0.001) and erythrocyte sedimentation rate (ESR) (p = 0.005), while males had higher neutrophil (p = 0.040) levels. Papillary thyroid cancer patients under 55 years had higher PLT (p < 0.001) and PCT (p = 0.010), while patients over 55 years had higher mean platelet volume (p = 0.032), neutrophil-to-lymphocyte ratio (p = 0.013), ESR (p = 0.005) and fibrinogen (p = 0.019) levels. Preoperative values for platelet indices and inflammatory markers were similar to the postoperative determinations in PTC patients. Fibrinogen (AUROC = 0.602, p = 0.02; cut-off = 327.5 mg/dL, Se = 53.8%, Sp = 62.9%) and PLT (AUROC = 0.584, p = 0.012; cut-off = 223.5 × 103/mm3, Se = 73.1%, Sp = 42.6%) were independent predictors of the presence of PTC. Conclusions: Our data show that fibrinogen and platelet count could be promising, inexpensive, independent predictors for the presence of PTC when compared with benign thyroid disorders.

Sign in / Sign up

Export Citation Format

Share Document